First-in-human Phase 1 clinical trial of RIPK1 inhibitor in healthy volunteers.

Trial Profile

First-in-human Phase 1 clinical trial of RIPK1 inhibitor in healthy volunteers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs DNL-747 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 26 Mar 2018 New trial record
    • 19 Mar 2018 According to Denali Therapeutics Inc media release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top